Belvarafenib for use in treatment of brain cancers
AssigneesGenentech, Inc., Hoffmann-La Roche Inc., Hanmi Pharm. Co., Ltd.
InventorsJoanne Adamkewicz, Michael John Dolton, Shiva Malek, Piia Thomas, Jennifer Eng-Wong, Yibing Yan, Young Hoon KIM, Young Gil AHN, Yu Yon KIM
Life of this patent
Estimating the term…
Abstract
Provided are methods for the use of belvarafenib to treat brain cancer including metastatic brain cancer carrying a BRAF mutation, a NRAS mutation, a KRAS mutation, or a combination thereof.
Claims62
A method of treating metastatic melanoma comprising administering to a subject in need thereof an amount of belvarafenib effective to treat the metastatic melanoma, wherein the site of metastasis is within the subject's brain.
A method of treating a brain cancer, the method comprising:
- (i) administering to a subject in need thereof a therapeutically effective amount of belvarafenib, or a pharmaceutically acceptable salt thereof, to treat the brain cancer;
- (ii) wherein administration of the belvarafenib inhibits the growth and viability of brain cancer cells in said subject;
- and
- (iii) wherein the brain cancer is characterized by a mutated MAPK signaling pathway.
A method of treating brain cancer, the method comprising:
- (i) administering to a subject in need thereof a therapeutically effective amount of belvarafenib, or a pharmaceutically acceptable salt thereof;
- (ii) administering to the subject an effective amount of a MEK inhibitor, or a pharmaceutically acceptable salt thereof,
- (iii) wherein administration of the belvarafenib and the MEK inhibitor inhibits the growth and viability of brain cancer cells in said subject;
- and
- (iv) wherein the brain cancer is characterized by a mutated MAPK signaling pathway.
Dependencies are inferred from the claim text.